Birk Venture

Founded in 2020, Accession Therapeutics is a UK-based biotechnology company developing innovative immuno-oncology therapeutics. Its proprietary platform enables targeted and potent immunotherapy, designed to combat tumor diversity by activating the full immune system arsenal while sparing healthy cells.

Founded in 2020, Accession Therapeutics is a UK-based biotechnology company developing innovative immuno-oncology therapeutics. Its proprietary platform enables targeted and potent immunotherapy, designed to combat tumor diversity by activating the full immune system arsenal while sparing healthy cells.

Zelluna Immunotherapy is a Norwegian biopharmaceutical company focused on developing T-cell receptor based cancer immunotherapies. Founded in 2016 and based in Oslo, it pursues a pipeline of tumor-specific TCRs, many derived from patients who showed long-term survival after peptide-based cancer vaccine trials at the Norwegian Radium Hospital/Oslo University Hospital. The company aims to enable immune cells to recognize a broad range of cancers with safety and durability. It operates in collaboration with Oslo Cancer Cluster and is located at the Oslo Cancer Cluster Innovation Park near major hospital facilities and GMP-certified cellular therapy capabilities.

APIM Therapeutics develops innovative peptide drugs targeting Proliferating Cell Nuclear Antigen (PCNA), a key protein regulating cellular responses to DNA damage and stress in cancer cells. Founded on groundbreaking research from NTNU, Trondheim, Norway, the company aims to eliminate and cure cancer-specific tumor cells.

Circio Holding ASA is a clinical-stage biotechnology company dedicated to developing and commercializing immuno-oncology therapies aimed at treating resistant solid tumors. The company's lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus designed to infect cancer cells and stimulate the immune system's response against tumors. In addition to ONCOS-102, Circio is advancing other candidates in its pipeline, including circVec and Mutant KRAS, which focus on targeted immunotherapy treatments for cancer patients. The company's innovative approach leverages cutting-edge genetic engineering to enhance the efficacy of cancer treatments, with a commitment to addressing the challenges posed by treatment-resistant cancers.

APIM Therapeutics develops innovative peptide drugs targeting Proliferating Cell Nuclear Antigen (PCNA), a key protein regulating cellular responses to DNA damage and stress in cancer cells. Founded on groundbreaking research from NTNU, Trondheim, Norway, the company aims to eliminate and cure cancer-specific tumor cells.

BerGenBio is a clinical-stage biotechnology company focused on developing novel therapies targeting aggressive cancers. Its lead drug candidate, bemcentinib (BGB324), is an oral small molecule inhibitor of AXL receptor tyrosine kinase, currently in clinical development for various cancer indications.

Nextera develops novel therapeutic drugs across autoimmune diseases, chronic infections, and cancer, leveraging a versatile platform built on protein engineering and evolution to enable high-resolution target discovery and lead candidate development, including strategies focused on HLA class II–associated mechanisms. All lead programs are paired with a companion diagnostic tied to the applied discovery tools to support precision treatment. The company aims to improve therapeutic efficacy while reducing off-target effects, differentiating itself through its integrated discovery platform and diagnostic capability to guide disease-specific therapy.

Nordic Nanovector is a biopharmaceutical company focused on developing innovative therapeutics for haematological cancers. Its lead product, Betalutin, an antibody-radionuclide-conjugate, is in clinical trials for treating non-Hodgkin lymphoma. The company aims to commercialize its products while building a pipeline of novel therapies.